Patient Registry for Individuals With CABP2-Associated Hearing Loss
Conditions: CABP2-related Auditory Synaptopathy, Hearing Impairment
Sponsor: University Medical Center Goettingen

 
 
“Hereditary Hearing Impairment Patient Registry” Version 2.1, 01.02.2025 
 
1/1 
ClinicalTrials.gov Identifier: NCT06680934 
 
May 16th, 2025 
CABP2 Registry 
 
What is the CABP2 Registry? 
The CABP2 Registry collects clinical information (various hearing tests and medical information) as 
well as genetic (Calcium-binding protein 2, CABP2) mutation details for research and therapy 
development. Through consent and participation, the CABP2 Registry aims to advance scientific 
knowledge by connecting (pseudonymized) patient data with scientists at the Institute for Auditory 
Neuroscience at University Medical Center Goettingen who have shown decades-long interest in 
understanding the mechanisms of several forms of hereditary hearing impairment, among which 
includes CABP2. 
 
In a collaboration between the Institute for Auditory Neuroscience and the Institute of Human 
Genetics at University Medical Center Goettingen, we have initiated a study wherein we aim to 
collect and evaluate the clinical and genetic findings of individuals with mutations in the CABP2 
gene. This will allow us to better understand the relationship between mutations and hearing loss 
and to improve patient care as new therapies are optimized. To support this goal, we have 
established a patient registry for voluntary participation and sharing of clinical and genetic 
information in questionnaire form. 
 
This registry study was approved by the Ethics Committee of the University Medical Center 
Goettingen (Approval: 17/8/22; Study Center ID: 2023-02528). 
 
Who can participate in the CABP2 Registry? 
The CABP2 Registry is open to the global CABP2 community that includes parents and legal 
guardians, as well as individuals who have been diagnosed with hearing impairment due to CABP2 
mutations. 
 
Where can participants find out more information? 
 
We invite prospective participants to review detailed study information and submit consent 
(http://www.auditory-neuroscience.uni-goettingen.de/cabp2_registry_en.html). This also includes 
information about the processing of personal data. 
 
Who can participants contact for more information? 
If you have questions or would like further clarification about the procedure, please contact the 
study manager, Dr. Barbara Vona, via email: barbara.vona@med.uni-goettingen.de. 
 
Project manager: 
Dr. Barbara Vona 
Institute for Auditory Neuroscience 
Robert-Koch-Str. 40 
37075 Göttingen, Germany 
Tel: (+49) 551-38-51337 
Email: barbara.vona@med.uni-goettingen.de 
 
 Institute for Auditory Neuroscience
Director: Prof. Dr. Tobias Moser
Robert-Koch-Str. 40, 37075 Göttingen, Germany
Department of Otolaryngology
Prof. Dr. med. Nicola Strenzke
Robert-Koch-Str. 40, 37075 Göttingen, Germany
Institute of Human Genetics
Director: Prof. Dr. med. Bernd Wollnik
Heinrich-Düker-Weg 12, 37073 Göttingen, Germany